Clin Oncol | Volume 2, Issue 1 | Mini Review | Open Access

Neurolymphomatosis: Treatment Response and Progression Monitored by 18F-FDG PET/CT

Pierre Abouhamad¹, Roger Denays^2*, Vincent Baudrez³, Jasmine Nguyen⁴, Thierry Dereme¹ and Jean-Philippe Hermanne⁴

¹Department of Nuclear Medicine, Rega Institute for Medical Research, Belgium
²Department of Neurology, Rega Institute for Medical Research, Belgium
³Department of Radiology, Rega Institute for Medical Research, Belgium
⁴Department of Hemato-Oncology, Rega Institute for Medical Research, Belgium

^*Correspondance to: Roger Denays 

Abstract

Neurolymphomatosis (NL)) is the term for infiltration of the peripheral nervous system by neurotropic neoplastic cells in the setting of a known or unknown haematological malignancy. Optimal treatment management of this rare clinical entity remains ill defined. We report the case of a 65-year-old woman with plexiform NL of the right sciatic nerve. Initial complete response to systemic chemotherapy, and later, relapse and progression, were accurately assessed by sequential 18-FDG-PET/CT studies, performed after a few cycles of the initial chemotherapy, and following completion of both initial treatment and salvage therapy.

Keywords:

Neurolymphomatosis; PET/CT; Response assessment

Citation:

Abouhamad P, Denays R, Baudrez V, Nguyen J, Dereme T, Hermanne J-P. Neurolymphomatosis: Treatment Response and Progression Monitored by 18F-FDG PET/CT. Clin Oncol. 2017; 2: 1305.